S-1/A: Allarity Therapeutics Seeks $8 Million in Best Efforts Offering to Fund Stenoparib Trial and Repurchase Preferred Stock

Allarity Therapeutics aims to raise up to $8 million through a best efforts offering of common stock, warrants, and pre-funded warrants to advance its stenoparib clinical trial and potentially repurchase Series A Preferred Stock.

Summary

• Allarity Therapeutics is conducting a best efforts offering to raise up to $8 million.
• The offering includes shares of common stock, Series A and Series B common stock purchase warrants, and pre-funded warrants.
• The assumed combined public offering price is $0.3011 per share, based on the last sale price on March 28, 2024.
• The Series A warrants expire in 5 years, and the Series B warrants expire in 2 years, both exercisable upon issuance at $0.3011 per share.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits of 4.99% or 9.99%.
• The company intends to use the net proceeds for potential payments under license agreements, continuation of the stenoparib clinical trials, payment of outstanding account payables and accrued liabilities, and working capital and general corporate purposes.
• 3i, LP, a major shareholder, may participate in the offering, and proceeds from their participation may be used to repurchase a portion of their Series A Preferred Stock.
• The offering will terminate no later than an unspecified date in 2024.
• The Nasdaq Listing Qualifications staff is seeking delisting of Allarity's shares, with an extension granted until April 24, 2024, to regain compliance.
• The company has effected multiple reverse stock splits, including a 1-for-20 reverse stock split on April 4, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing funding and clinical trials, the risk of delisting and potential dilution of shareholder value temper the positive aspects.

Positives

• The offering aims to fund the clinical development of stenoparib, a promising oncology therapeutic.
• Potential repurchase of Series A Preferred Stock could simplify the company's capital structure.
• The company has secured an extension to maintain its Nasdaq listing, providing more time to regain compliance.

Negatives

• The company is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• The offering is on a 'best efforts' basis, meaning there's no guarantee the full $8 million will be raised.
• Existing shareholders face potential dilution from the issuance of new shares and warrants.
• The company has a history of non-compliance and currently are not in compliance with the continued listing requirements.

Risks

• Failure to meet Nasdaq continued listing requirements could lead to delisting and decreased stock value.
• The company's use of proceeds may not increase the value of your investment.
• There is no public market for the pre-funded warrants and common warrants to purchase Common Stock in this offering.
• New investors will experience immediate and substantial dilution.
• The company has granted certain rights to certain holders of our securities which limits our ability to raise funds from the sale of our securities.
• The company received a request for documents from the SEC in the investigation known as In the Matter of Allarity Therapeutics, Inc., and, separately, a letter from Nasdaq, regarding the same matter, the consequences of which are unknown.
• If the company's business developments and achievements do not meet the expectations of investors or securities analysts or for other reasons the expected benefits do not occur, the market price of shares of our Common Stock traded on Nasdaq may decline.
• The price of shares of our Common Stock has fluctuated substantially.
• The company is subject to penalties if it fails to meet certain conditions of the Certificate of Designations of the Series A Preferred Stock.
• The company's continued operations are dependent on it raising capital.
• Future sales, or the perception of future sales, by the company or its stockholders in the public market could cause the market price for shares of its Common Stock to decline.
• Because there are no current plans to pay cash dividends on shares of the company's Common Stock for the foreseeable future, you may not receive any return on investment unless you sell your shares of Common Stock for a price greater than that which you paid for it.
• The company may incur substantial penalties if it fails to maintain the effectiveness of its registration statement covering the resale of shares of its Common Stock issued to 3i, upon conversion of its Series A Preferred Stock, and the shares of Common Stock issuable upon the exercise of the Inducement Warrants by the September Investors.
• There is no assurance that an active and liquid trading market in shares of the company's Common Stock will develop.
• The company's Certificate of Incorporation and its bylaws, and Delaware law, may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause its stock price to decline.
• The company's Certificate of Incorporation designates the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) as the exclusive forum for certain types of claims that the federal courts do not have exclusive jurisdiction, which may limit a stockholders ability to bring a claim in a judicial forum that it finds favorable.

Future Outlook

The company intends to use the net proceeds of this offering towards potential payments under license agreements, continuation of its stenoparib clinical trials, payment of outstanding account payables and accrued liabilities, and working capital and general corporate purposes.

Industry Context

The announcement reflects the ongoing challenges faced by small-cap biotech companies in securing funding and navigating regulatory hurdles, particularly in the competitive oncology space.

Comparison to Industry Standards

• The 'best efforts' underwriting approach is common for smaller companies but carries execution risk compared to firm commitment underwritings.
• Reverse stock splits are frequently used by companies facing delisting to artificially inflate share prices and regain compliance, but they can negatively impact investor sentiment.
• The use of proceeds to repurchase preferred stock is a strategic decision that can be viewed positively if it simplifies the capital structure, but it may raise concerns if it diverts funds from core R&D activities.
• Comparable companies in similar situations include those listed on the Nasdaq SmallCap Market facing compliance issues, such as XOMA Corporation and Diffusion Pharmaceuticals, Inc.

Legal Proceedings

• The company received a request for documents from the SEC in the investigation known as In the Matter of Allarity Therapeutics, Inc., and, separately, a letter from Nasdaq, regarding the same matter, the consequences of which are unknown.

Related Party Transactions

• 3i, LP, a major shareholder, may participate in the offering, and proceeds from their participation may be used to repurchase a portion of their Series A Preferred Stock.

Stakeholder Impact

• Shareholders face potential dilution and the risk of delisting.
• Employees' job security could be affected by the company's financial stability.
• The success of stenoparib clinical trials could impact patients with difficult-to-treat cancers.
• Creditors and suppliers face increased risk if the company fails to secure sufficient funding.

Next Steps

• Complete the offering and secure funding.
• Continue the Phase 2 clinical trial of stenoparib.
• Regain compliance with Nasdaq listing requirements by April 24, 2024.
• Negotiate the actual combined public offering price of the shares of Common Stock and common warrants, and pre-funded warrants and common warrants, and the exercise price of the common warrants that are being offered, with the placement agent and the investors in the offering.

Key Dates

Keywords

Allarity Therapeutics, common stock, warrants, pre-funded warrants, stenoparib, offering, Nasdaq, clinical trial, Series A Preferred Stock, 3i, delisting, compliance